443 related articles for article (PubMed ID: 20435194)
1. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.
O'Connor CM; Miller AB; Blair JE; Konstam MA; Wedge P; Bahit MC; Carson P; Haass M; Hauptman PJ; Metra M; Oren RM; Patten R; Piña I; Roth S; Sackner-Bernstein JD; Traver B; Cook T; Gheorghiade M;
Am Heart J; 2010 May; 159(5):841-849.e1. PubMed ID: 20435194
[TBL] [Abstract][Full Text] [Related]
2. Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial).
Shah AN; Mentz RJ; Gheorghiade M; Kwasny MJ; Fought AJ; Zannad F; Swedberg K; Maggioni AP; Konstam MA
Am J Cardiol; 2012 Dec; 110(12):1803-8. PubMed ID: 22999071
[TBL] [Abstract][Full Text] [Related]
3. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program.
Blair JE; Zannad F; Konstam MA; Cook T; Traver B; Burnett JC; Grinfeld L; Krasa H; Maggioni AP; Orlandi C; Swedberg K; Udelson JE; Zimmer C; Gheorghiade M;
J Am Coll Cardiol; 2008 Nov; 52(20):1640-8. PubMed ID: 18992654
[TBL] [Abstract][Full Text] [Related]
4. Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial.
Payvar S; Spertus JA; Miller AB; Casscells SW; Pang PS; Zannad F; Swedberg K; Maggioni AP; Reid KJ; Gheorghiade M;
Eur J Heart Fail; 2013 Dec; 15(12):1382-9. PubMed ID: 23858000
[TBL] [Abstract][Full Text] [Related]
5. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction.
Udelson JE; McGrew FA; Flores E; Ibrahim H; Katz S; Koshkarian G; O'Brien T; Kronenberg MW; Zimmer C; Orlandi C; Konstam MA
J Am Coll Cardiol; 2007 Jun; 49(22):2151-9. PubMed ID: 17543634
[TBL] [Abstract][Full Text] [Related]
6. EVEREST study: Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan.
Cavalcante JL; Khan S; Gheorghiade M
Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1331-8. PubMed ID: 19018685
[TBL] [Abstract][Full Text] [Related]
7. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial.
Blair JE; Pang PS; Schrier RW; Metra M; Traver B; Cook T; Campia U; Ambrosy A; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Konstam MA; Gheorghiade M;
Eur Heart J; 2011 Oct; 32(20):2563-72. PubMed ID: 21785107
[TBL] [Abstract][Full Text] [Related]
8. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.
Gheorghiade M; Böhm M; Greene SJ; Fonarow GC; Lewis EF; Zannad F; Solomon SD; Baschiera F; Botha J; Hua TA; Gimpelewicz CR; Jaumont X; Lesogor A; Maggioni AP;
JAMA; 2013 Mar; 309(11):1125-35. PubMed ID: 23478743
[TBL] [Abstract][Full Text] [Related]
9. Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial.
Blair JE; Khan S; Konstam MA; Swedberg K; Zannad F; Burnett JC; Grinfeld L; Maggioni AP; Udelson JE; Zimmer CA; Ouyang J; Chen CF; Gheorghiade M;
Eur Heart J; 2009 Jul; 30(13):1666-73. PubMed ID: 19411662
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).
Greene SJ; Harinstein ME; Vaduganathan M; Subačius H; Konstam MA; Zannad F; Maggioni AP; Swedberg K; Butler J; Gheorghiade M;
Am J Cardiol; 2012 Dec; 110(11):1657-62. PubMed ID: 22917555
[TBL] [Abstract][Full Text] [Related]
11. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
Ambrosy AP; Vaduganathan M; Mentz RJ; Greene SJ; Subačius H; Konstam MA; Maggioni AP; Swedberg K; Gheorghiade M
Am Heart J; 2013 Feb; 165(2):216-25. PubMed ID: 23351825
[TBL] [Abstract][Full Text] [Related]
12. Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials.
Pang PS; Gheorghiade M; Dihu J; Swedberg K; Khan S; Maggioni AP; Grinfeld L; Zannad F; Burnett JC; Ouyang J; Udelson JE; Konstam MA
Am Heart J; 2011 Jun; 161(6):1067-72. PubMed ID: 21641352
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
Vaduganathan M; Ambrosy AP; Greene SJ; Mentz RJ; Subacius HP; Maggioni AP; Swedberg K; Nodari S; Zannad F; Konstam MA; Butler J; Gheorghiade M;
Circ Heart Fail; 2012 Nov; 5(6):750-8. PubMed ID: 23051949
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).
Greene SJ; Vaduganathan M; Lupi L; Ambrosy AP; Mentz RJ; Konstam MA; Nodari S; Subacius HP; Fonarow GC; Bonow RO; Gheorghiade M;
Am J Cardiol; 2013 Feb; 111(4):574-81. PubMed ID: 23206923
[TBL] [Abstract][Full Text] [Related]
15. Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial.
Mentz RJ; Chung MJ; Gheorghiade M; Pang PS; Kwasny MJ; Ambrosy AP; Vaduganathan M; O'Connor CM; Swedberg K; Zannad F; Konstam MA; Maggioni AP
Am Heart J; 2012 Dec; 164(6):884-92.e2. PubMed ID: 23194489
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment.
Vaduganathan M; Gheorghiade M; Pang PS; Konstam MA; Zannad F; Swedberg K; Grinfeld L; Burnett JC; Krasa HB; Zimmer C; Blair J; Ouyang J; Maggioni AP;
J Cardiovasc Med (Hagerstown); 2012 Jul; 13(7):415-22. PubMed ID: 22673023
[TBL] [Abstract][Full Text] [Related]
17. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
Gheorghiade M; Gattis WA; O'Connor CM; Adams KF; Elkayam U; Barbagelata A; Ghali JK; Benza RL; McGrew FA; Klapholz M; Ouyang J; Orlandi C;
JAMA; 2004 Apr; 291(16):1963-71. PubMed ID: 15113814
[TBL] [Abstract][Full Text] [Related]
18. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
Konstam MA; Gheorghiade M; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Cook T; Ouyang J; Zimmer C; Orlandi C;
JAMA; 2007 Mar; 297(12):1319-31. PubMed ID: 17384437
[TBL] [Abstract][Full Text] [Related]
19. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry.
Senni M; Gavazzi A; Oliva F; Mortara A; Urso R; Pozzoli M; Metra M; Lucci D; Gonzini L; Cirrincione V; Montagna L; Di Lenarda A; Maggioni AP; Tavazzi L;
Int J Cardiol; 2014 May; 173(2):163-9. PubMed ID: 24630337
[TBL] [Abstract][Full Text] [Related]
20. Implantable cardioverter-defibrillators in patients hospitalized for heart failure with chronically reduced left ventricular ejection fraction.
Wang NC; Piccini JP; Konstam MA; Maggioni AP; Traver B; Swedberg K; Udelson JE; Zannad F; Cook T; O'Connor CM; Miller AB; Grinfeld L; Gheorghiade M;
Am J Ther; 2010; 17(4):e78-87. PubMed ID: 20634650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
